Structured evidence table for Coenzyme Q10 Endothelial Function Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Coenzyme Q10 Endothelial Function Randomized Trial | Despite major advancements in pharmacotherapies and interventional cardiology, substantial residual risk persists among patients with established disease (). | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
| Coenzyme Q10 Endothelial Function Randomized Trial | Additionally, many nutraceuticals are perceived to possess favorable safety and tolerability profiles compared to conventional medications, making them attractive for long-term risk reduction (). | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
| Coenzyme Q10 Endothelial Function Randomized Trial | Banach et al., 2018 Cicero et al., 2017 Sesso et al., 2008 However, the field is marked by heterogeneous and sometimes contradictory evidence. | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
| Coenzyme Q10 Endothelial Function Randomized Trial | Roth et al., 2020 Ganda et al., 2018 Visseren et al., 2021 Cardiovascular disease (CVD) is the leading cause of mortality worldwide, accounting for nearly one-third of global deaths each year (). | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
| Coenzyme Q10 Endothelial Function Randomized Trial | However, interventional approaches are invasive and costly, while pharmacological therapies are frequently limited by long-term adherence challenges, drug intolerance, and residual cardiovascular risk. | 4 | Alabrahim Obaydah Abd Alkader (2026) | Reengineering statin therapy to protect skeletal muscle: nanocarrier strategies for mitigating mitochondrial dysfunction and myotoxicity |
| Coenzyme Q10 Endothelial Function Randomized Trial | Despite these benefits, statin therapy is often compromised by muscle-related adverse effects, collectively referred to as statin-associated myopathy (SAM). | 4 | Alabrahim Obaydah Abd Alkader (2026) | Reengineering statin therapy to protect skeletal muscle: nanocarrier strategies for mitigating mitochondrial dysfunction and myotoxicity |
| Coenzyme Q10 Endothelial Function Randomized Trial | Lipophilic statins, such as simvastatin and atorvastatin, are particularly associated with a higher incidence of muscular symptoms, likely due to their enhanced penetration into extrahepatic tissues [,]. | 4 | Alabrahim Obaydah Abd Alkader (2026) | Reengineering statin therapy to protect skeletal muscle: nanocarrier strategies for mitigating mitochondrial dysfunction and myotoxicity |
| Coenzyme Q10 Endothelial Function Randomized Trial | 1 2 3 World Heart Report 2023 Cardiovascular diseases (CVDs) remain the leading cause of mortality and disability worldwide, imposing a substantial burden on global healthcare systems and economies. | 4 | Alabrahim Obaydah Abd Alkader (2026) | Reengineering statin therapy to protect skeletal muscle: nanocarrier strategies for mitigating mitochondrial dysfunction and myotoxicity |
Source documents